A single-center experience of haploidentical stem cell transplantation in hematological malignancies
Yıl: 2023 Cilt: 53 Sayı: 1 Sayfa Aralığı: 352 - 359 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5591 İndeks Tarihi: 29-03-2023
A single-center experience of haploidentical stem cell transplantation in hematological malignancies
Öz: Background/aim: Since well-designed prospective comparative trials are lacking, haploidentical hematopoietic stem cell transplantations approach should be based on the expertise of a particular center. In this study, we aimed to report the results and outcomes of patients who underwent haploidentical hematopoietic stem cell transplantation. Materials and methods: Thirty-nine patients who underwent transplantation in our clinic between 2015 and 2022 were retrospectively analyzed. Primary end point of this study is to find out the survival rates of the patients. Results: The overall survival of patients was 29.9 ± 4.9 months. The disease-free survival of the patients was 37.8 ± 5.7 months. The 3-year overall survival rate of the patients was %50 and the 3-year disease-free survival rate of the patients was %53. Nineteen patients were nonsurvivors among a total of 39 patients. Busulfan–fludarabine–thiotepa was the most frequently used conditioning regimen for transplantation. Busulfan–fludarabin–antithymocyte globulin regimen is the second preferred conditioning regimen. Cyclosporine– cyclophosphamide–mycophenolate mofetil was the most widely used graft-versus-host disease prophylaxis regimen. Sixteen patients had graft-versus-host disease, 28% of the patients had acute graft-versus-host disease, and 13% had chronic graft-versus-host disease. Gastrointestinal system consists of the most involved organs in graft-versus-host disease since 15% of the patients had gastrointestinal graft-versus-host disease. First-degree relatives (parent/child) were the most frequent donor source for haploidentical hematopoietic stem cell transplantation. Sepsis was the most frequent reason of death among transplant patients. Conclusion: In our center, we prefer to use high dose posttransplantation cyclophosphamide after haploidentical hematopoietic stem cell transplantation for graft-versus-host disease prophylaxis. With this approach, our center’s overall survival and disease-free survival rates are comparable and compatible with the literature findings.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nature Reviews Clinical Oncology 2016; 13: 10-24. https://doi.org/ 10.1038/nrclinonc.2015.128
- 2. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplantation 2016; 51: 786-792. https://doi.org/10.1038/bmt.2016.20
- 3. Sugita J. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. International journal of hematology 2019; 110: 30-38. https://doi.org/10.1007/s12185- 019-02660-8
- 4. O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation 2002; 8: 377-386. https://doi. org/10.1053/bbmt.2002.v8.pm12171484
- 5. Aladağ Karakulak E, Demİroğlu H, Malkan UY, Akman U, Göker H et al. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Turkish Journal of Medical Sciences 2021; 51: 355-358. https://doi.org/10.3906/ sag-2007-17
- 6. Sengsayadeth S, Savani BN, Blaise D, Mohty M. Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. Seminars in Hematology 2016; 53: 111-114. https://doi.org/10.1053/j.seminhematol.2016.01.012
- 7. Pagliardini T, Castagna L, Harbi S, Porta MD, Rey J et al. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. Biology of Blood and Marrow Transplantation 2019; 25: 1803-1809. https://doi.org/10.1016/j.bbmt.2019.05.014
- 8. El-Cheikh J, Devillier R, Dulery R, Massoud R, Al Chami F et al. Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. Clinical Lymphoma, Myeloma & Leukemia 2020; 20: 617-623. https://doi.org/10.1016/j. clml.2020.04.003
- 9. Gragert L, Eapen M, Williams E, Freeman J, Spellman S et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. New England Journal of Medicine 2014; 371: 339-348. https://doi.org/10.1056/NEJMsa1311707
- 10. Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991- 2000). Blood 2003; 102: 1541-1547. https://doi.org/10.1182/ blood-2003-02-0430
- 11. Wang Y, Liu DH, Xu LP, Liu KY, Chen H et al. Superior graft- versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biology of Blood and Marrow Transplantation 2011; 17: 821- 830. https://doi.org/10.1016/j.bbmt.2010.08.023
- 12. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. Journal of Clinical Oncology 1997; 15: 1767-1777. https://doi.org/10.1200/ JCO.1997.15.5.1767
- 13. Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplantation 1991; 7: 443-452.
- 14. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplantation 2006; 38: 291-297. https://doi. org/10.1038/sj.bmt.1705445
- 15. Liu D, Huang X, Liu K, Xu L, Chen H et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biology of Blood and Marrow Transplantation 2008; 14: 469-477. https://doi.org/10.1016/j.bbmt.2008.02.007
- 16. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125: 3956-3962. https://doi.org/10.1182/blood-2015-02-627786
- 17. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post- transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. Journal of Clinical Oncology 2013; 31: 1310-1316. https://doi.org/10.1200/ JCO.2012.44.3523
- 18. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 2016; 127: 938-947. https://doi.org/10.1182/ blood-2015-09-671834
- 19. Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood 2021; 137: 3291-3305. https://doi.org/10.1182/ blood.2020009362
- 20. Saraceni F, Beohou E, Labopin M, Arcese W, Bonifazi F et al. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. American Journal of Hematology 2018; 93: 1211-1219. https://doi.org/10.1002/ajh.25225
- 21. Esquirol A, Pascual MJ, Kwon M, Pérez A, Parody R et al. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation 2021; 56: 2432-2444. https://doi.org/10.1038/ s41409-021-01328-4
- 22. Chang J, Hsiao M, Blodget E, Akhtari M. Increased risk of 100- day and 1-year infection-related mortality and complications in haploidentical stem cell transplantation. Journal of Blood Medicine 2019; 10: 135-143. https://doi.org/10.2147/JBM. S201073
- 23. Mulroney CM, Abid MB, Bashey A, Chemaly RF, Ciurea SO et al. Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft- versus-host disease prophylaxis and haploidentical stem cell transplantation. British Journal of Haematology 2021; 194: 145-157. https://doi.org/10.1111/bjh.17563
- 24. Atilla E, Atilla PA, Bozdağ SC, Demirer T. A review of infectious complications after haploidentical hematopoietic stem cell transplantations. Infection 2017; 45: 403-411. https:// doi.org/10.1007/s15010-017-1016-1
- 25. Robinson TM, O’Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Seminars in Hematology 2016; 53: 90-97. https://doi. org/10.1053/j.seminhematol.2016.01.005
- 26. Hernani R, Piñana JL, Pérez A, Quintero A, Montoro J et al. Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. eJHaem 2021; 2: 236-248. https://doi.org/10.1002/ jha2.183
- 27. Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E et al. Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation 2016; 22: 23-26. https://doi.org/10.1016/j.bbmt.2015.11.001
- 28. Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature 1959; 183: 1682-1683. https://doi. org/10.1038/1831682a0
- 29. Berenbaum M, Brown I. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 1963; 200: 84. https://doi.org/10.1038/200084a0.
- 30. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120: 905-913. https://doi. org/10.1182/blood-2012-03-418202
- 31. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biology of Blood and Marrow Transplantation 2012; 18: 1859- 1866. https://doi.org/10.1016/j.bbmt.2012.06.019
- 32. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biology of Blood and Marrow Transplantation 2014; 20: 1573- 1579. https://doi.org/10.1016/j.bbmt.2014.05.029
| APA | MALKAN Ü, Göker H, Demiroglu H, Tekin F, Akdemir B, Aladag E, Sayınalp N, Haznedaroglu I, Özcebe O, Buyukasik Y (2023). A single-center experience of haploidentical stem cell transplantation in hematological malignancies. , 352 - 359. 10.55730/1300-0144.5591 |
| Chicago | MALKAN Ümit Yavuz,Göker Hakan,Demiroglu Haluk,Tekin Fatma,Akdemir Buket,Aladag Elifcan,Sayınalp Nilgün,Haznedaroglu Ibrahim C.,Özcebe Osman,Buyukasik Yahya A single-center experience of haploidentical stem cell transplantation in hematological malignancies. (2023): 352 - 359. 10.55730/1300-0144.5591 |
| MLA | MALKAN Ümit Yavuz,Göker Hakan,Demiroglu Haluk,Tekin Fatma,Akdemir Buket,Aladag Elifcan,Sayınalp Nilgün,Haznedaroglu Ibrahim C.,Özcebe Osman,Buyukasik Yahya A single-center experience of haploidentical stem cell transplantation in hematological malignancies. , 2023, ss.352 - 359. 10.55730/1300-0144.5591 |
| AMA | MALKAN Ü,Göker H,Demiroglu H,Tekin F,Akdemir B,Aladag E,Sayınalp N,Haznedaroglu I,Özcebe O,Buyukasik Y A single-center experience of haploidentical stem cell transplantation in hematological malignancies. . 2023; 352 - 359. 10.55730/1300-0144.5591 |
| Vancouver | MALKAN Ü,Göker H,Demiroglu H,Tekin F,Akdemir B,Aladag E,Sayınalp N,Haznedaroglu I,Özcebe O,Buyukasik Y A single-center experience of haploidentical stem cell transplantation in hematological malignancies. . 2023; 352 - 359. 10.55730/1300-0144.5591 |
| IEEE | MALKAN Ü,Göker H,Demiroglu H,Tekin F,Akdemir B,Aladag E,Sayınalp N,Haznedaroglu I,Özcebe O,Buyukasik Y "A single-center experience of haploidentical stem cell transplantation in hematological malignancies." , ss.352 - 359, 2023. 10.55730/1300-0144.5591 |
| ISNAD | MALKAN, Ümit Yavuz vd. "A single-center experience of haploidentical stem cell transplantation in hematological malignancies". (2023), 352-359. https://doi.org/10.55730/1300-0144.5591 |
| APA | MALKAN Ü, Göker H, Demiroglu H, Tekin F, Akdemir B, Aladag E, Sayınalp N, Haznedaroglu I, Özcebe O, Buyukasik Y (2023). A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish Journal of Medical Sciences, 53(1), 352 - 359. 10.55730/1300-0144.5591 |
| Chicago | MALKAN Ümit Yavuz,Göker Hakan,Demiroglu Haluk,Tekin Fatma,Akdemir Buket,Aladag Elifcan,Sayınalp Nilgün,Haznedaroglu Ibrahim C.,Özcebe Osman,Buyukasik Yahya A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish Journal of Medical Sciences 53, no.1 (2023): 352 - 359. 10.55730/1300-0144.5591 |
| MLA | MALKAN Ümit Yavuz,Göker Hakan,Demiroglu Haluk,Tekin Fatma,Akdemir Buket,Aladag Elifcan,Sayınalp Nilgün,Haznedaroglu Ibrahim C.,Özcebe Osman,Buyukasik Yahya A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish Journal of Medical Sciences, vol.53, no.1, 2023, ss.352 - 359. 10.55730/1300-0144.5591 |
| AMA | MALKAN Ü,Göker H,Demiroglu H,Tekin F,Akdemir B,Aladag E,Sayınalp N,Haznedaroglu I,Özcebe O,Buyukasik Y A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish Journal of Medical Sciences. 2023; 53(1): 352 - 359. 10.55730/1300-0144.5591 |
| Vancouver | MALKAN Ü,Göker H,Demiroglu H,Tekin F,Akdemir B,Aladag E,Sayınalp N,Haznedaroglu I,Özcebe O,Buyukasik Y A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish Journal of Medical Sciences. 2023; 53(1): 352 - 359. 10.55730/1300-0144.5591 |
| IEEE | MALKAN Ü,Göker H,Demiroglu H,Tekin F,Akdemir B,Aladag E,Sayınalp N,Haznedaroglu I,Özcebe O,Buyukasik Y "A single-center experience of haploidentical stem cell transplantation in hematological malignancies." Turkish Journal of Medical Sciences, 53, ss.352 - 359, 2023. 10.55730/1300-0144.5591 |
| ISNAD | MALKAN, Ümit Yavuz vd. "A single-center experience of haploidentical stem cell transplantation in hematological malignancies". Turkish Journal of Medical Sciences 53/1 (2023), 352-359. https://doi.org/10.55730/1300-0144.5591 |
